Genspeed Biotech

Executive Summary

Genspeed Biotech, headquartered in Vienna, Austria, has developed a groundbreaking point-of-care diagnostic platform called GENSPEED xPOC, which can quantify up to eight biomarkers from a single drop of capillary blood in just 15 minutes. This innovative immuno-multiplex technology is designed to accelerate personalized medicine by enabling rapid, multi-parameter testing at the point of need. The company's platform is already CE-IVD and IVDR certified, and it offers an OEM model to partners looking to commercialize their own assays. With a focus on decentralized diagnostics, Genspeed is poised to address growing demand for rapid, accessible testing in clinical, primary care, and remote settings. While the company remains private and has not disclosed funding or valuation, its technology positions it as a potential disruptor in the diagnostics space, particularly in applications such as infectious disease, cardiac markers, and inflammation panels. The platform's ability to deliver lab-quality results from minimal sample volumes could unlock new market opportunities and make significant contributions to personalized healthcare.

Upcoming Catalysts (preview)

• Q4 2026FDA Clearance for GENSPEED xPOC Platform or Specific Assay Panel60% success
• Q2 2026Strategic Partnership with Diagnostic Distributor or Pharma Company70% success
• H1 2026Series A or B Funding Round Announcement65% success